Clinical Trial

ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2020 (before its estimated October 1, 2022 completion). Its status may not reflect the trial's current state.
Summary
The main objective of the phase I/II trial is to determine the safety and efficacy of a single fraction SBRT at a dose of 19 Gy in patients with localized prostate cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2017-09-22; most recent amendment 2020-05-13.
Status change: Not Yet Recruiting → Recruiting 2018-01-24
Trial Details
NCT Number NCT03294889
Lead Sponsor University Hospital, Geneva
Collaborators: Humanitas Hospital, Italy, University of Zurich, Kantonsspital Graubünden
Conditions Prostate Cancer
Enrollment 45 participants
Start Date 2017-09-01
Primary Completion 2022-10-01 (estimated)
Study Completion 2030-10-01 (estimated)
Updated on ClinicalTrials.gov 2020-05-14